Thu, Apr 17, 2014, 6:19 AM EDT - U.S. Markets open in 3 hrs 11 mins


% | $
Quotes you view appear here for quick access.

Silver Wheaton Corp. Message Board

stocklooking 43 posts  |  Last Activity: 17 hours ago Member since: Dec 30, 1999
  • Reply to

    new 8-K

    by symptoms88 Apr 14, 2014 10:07 PM
    stocklooking stocklooking 17 hours ago Flag

    Too big egos of the new management. That's my feeling after reading the 8-K. They realized that they made a big mistake, but they don't want to admit it. That's why they don't even want to make a press release about TRUST-1 result and point out some positives to the public. I am still worried they will use the limited fund to buy some in-research products and devest TSO.
    Rosenwald, you were wrong firing Dr. Weisman, please don't try to cover that mistake with more mistakes at cost of your investors.

  • stocklooking stocklooking Apr 13, 2014 3:13 AM Flag

    Something wrong with special character searching, eg, , , :
    Benjamin T. Marchello
    Benjamin T. Marchello
    So, there are 80 PI's in total.

  • stocklooking stocklooking Apr 13, 2014 3:07 AM Flag

    Tried to find unique PIs, 81 in total:
    Addison R. Tolentino
    Alan P. Lyss
    Alison K. Conlin
    Anthony J. Jaslowski
    Aqeel A. Gillani
    Asheesh Shipstone
    Benjamin A. Gartrell
    Benjamin T. Marchello
    Benjamin T. Marchello
    Brian A. Costello
    Brian H. Kim
    Carla Kurkjian
    Charles S. Kuzma
    Christopher M. Reynolds
    Craig Swainey
    Daniel A. Vaena
    Daniel M. Anderson
    David M. Spector
    Dennie V. Jones
    Donald B. Wender
    Donald J. Jurgens
    Edward T. O'Brien
    Frederick M. Briccetti
    Gamini S. Soori
    George K. Philips
    Grant R. Seeger
    Harvey C. Lebos
    J. P. Monk
    James D. Bearden
    James E. Radford
    James M. Randall
    James N. Atkins
    Jay W. Carlson
    Jeffrey Crawford
    Jeffrey J. Kirshner
    Jeffrey K. Giguere
    Jeffrey L. Berenberg
    Jihad Khattab
    Joel Picus
    John A. Ellerton
    John H. Vu
    John P. Kuebler
    Joseph J. Merchant
    Justin P. Favaro
    Keith L. Shulman
    Keren Sturtz
    Lynn M. Steinbrenner
    Marc S. Ernstoff
    Mark T. Schroeder
    Michael O. Ojelabi
    Miroslaw A. Mazurczak
    Nadim F. Nimeh
    Nguyet A. Le-Lindqwister
    Peter R. Watson
    Preston D. Steen
    Rahul R. Aggarwal
    Rajesh Bajaj
    Rajiv Panikkar
    Ralph J. Hauke
    Raymond S. Lord
    Rex B. Mowat
    Robert A. Chapman
    Robert J. Behrens
    Robin T. Zon
    Saby George
    Saeeda Kirmani
    Sam Benjamin
    Scott T. Tagawa
    Seth O. Fagbemi
    Shadi M. Haddadin
    Shaker R. Dakhil
    Sharon D. Luikart
    Sreenivasa R. Nattam
    Stephen S. Grubbs
    Susanna Hong
    Thomas H. Openshaw
    Thomas P. Bradley
    Timothy R. Wassenaar
    Toni K. Choueiri
    Vikki A. Canfield
    Walter M. Stadler

  • stocklooking stocklooking Apr 13, 2014 2:23 AM Flag

    Colorado has 32 sites and only one PI. How powerful is this Dr. Keren Sturtz in colorado?

  • stocklooking stocklooking Apr 13, 2014 2:17 AM Flag

    150 enrollments for 366 sites, and no real placebo branch, that's weird. It should finish enrollment in less than one month.

  • Reply to


    by symptoms88 Apr 10, 2014 4:37 PM
    stocklooking stocklooking Apr 10, 2014 6:14 PM Flag

    Two major differences need to be heeded: 1) age, that's good, kids should be the main focus; 2) no specific allergy or parental allergy inclusion criteria as Hollander's. Will this general population open a bigger market, or decrease the efficacy statsig?

  • Reply to


    by symptoms88 Apr 10, 2014 4:37 PM
    stocklooking stocklooking Apr 10, 2014 5:46 PM Flag

    Finally, this long expected trial has started. Every time you search TSO in clinicaltrials, it pops up at first position. I actually emailed Itai one year ago asking if the trial was running, and got no response. Seems Hollander's trial result gave him the courage to continue.

  • Reply to

    boring, do my final exam

    by stocklooking Apr 10, 2014 1:11 AM
    stocklooking stocklooking Apr 10, 2014 1:24 AM Flag

    rough estimation, half person may be counted up or down without meaningful difference...

  • stocklooking by stocklooking Apr 10, 2014 1:11 AM Flag

    Waiting is a boring game, wanna check to see if I am too old to do my final EXAM preparation.
    Assumptions: 1) both placebo and dosing branches population decay at their own rates as they were from 4/5/2011 to 6/15/2012; 2) no dropouts; 3) no secrete crossover by patients.
    T0=0; 4/5/2011, population of cabo group 153, population of placebo group 81
    yc = 153exp(-Kct), yp = 81exp(-Kpt), y = yc+yp, where exp(x) means x power of e
    T1=436; 6/15/2012; yc = 116; yp=52
    solve Kc, Kp
    Kc = -ln(116/153)/436 = 0.00063497
    Kp = 0.0010165
    T2=970; 12/1/2013; y = 113; 55 events, ie, we reached 55 events on 12/1/2013.
    T3=1000; 12/31/2013; y = 110;
    T4=1090; 4/1/2014; y = 103; 65 events, 10 more than needed.
    Apparently, my assumption didn't hold. Unexpected drop out rates due to cabo approval and marketing after Jan2013? Estimation of Kc and Kp were too high, so there were less events happened on one or both branches? Since at T1, we had a low yp=52, little change of Kp wouldn't make a big dent in y(T4). Looking back before T0 and after, Kc's decreasing was more trendy and can make big difference with a factor of 116.
    Anyway, before the actual data come out, anything is just a guess.

  • Reply to

    It's so sad

    by stocklooking Apr 4, 2014 12:49 PM
    stocklooking stocklooking Apr 4, 2014 1:08 PM Flag

    NCT01948271 and see history of changes

  • stocklooking by stocklooking Apr 4, 2014 12:49 PM Flag

    They are gradually dropping TSO, not even inform shareholders. Tufts' ongoing psoriasis trial has been updated yesterday. CNDO was dropped from the sponsor's name list, and collaborators' list! That means management has contacted the research sites to dump TSO or you have to go alone.

  • stocklooking stocklooking Mar 27, 2014 1:49 AM Flag

    That trial has no prednisone control branch. Anybody has the OS data for heavily treated bone-metastasis patients on prednisone?

  • stocklooking by stocklooking Mar 26, 2014 4:08 PM Flag

    Only one sentence "Go ahead and finish the whole trial."? MMM should release more data than that!

  • Reply to

    Interim News

    by wildbiftek Mar 25, 2014 7:21 PM
    stocklooking stocklooking Mar 25, 2014 7:44 PM Flag

    OK, the waiting time might be shorter than I thought. Are they going to release some data on interim analysis tomorrow?

  • Reply to

    Final analysis date of COMET-1

    by stocklooking Mar 25, 2014 5:20 PM
    stocklooking stocklooking Mar 25, 2014 6:33 PM Flag

    Don't be so mean to me. Just try to warn my fellow longs that the waiting time MIGHT be much longer than you were told. It's a cheerful and painful message, depending on who you are. The probability is much bigger than 0. I may be completely wrong since I don't have enough info. But it's my guesstimate based on the available info.

  • Reply to

    Final analysis date of COMET-1

    by stocklooking Mar 25, 2014 5:20 PM
    stocklooking stocklooking Mar 25, 2014 6:14 PM Flag

    If you have to wait for 10 more years, that's good for human beings as a whole.
    Don't worry! The independent monitor board will end the trial long before 10 years.

  • Reply to

    Final analysis date of COMET-1

    by stocklooking Mar 25, 2014 5:20 PM
    stocklooking stocklooking Mar 25, 2014 6:10 PM Flag

    If cabo works great, we may have to wait across the line of year2014.
    Am I too optimistic or pessimistic? EXAM told me to be patient with its end-of-enrollment time guideline of march 2012.

  • stocklooking by stocklooking Mar 25, 2014 5:20 PM Flag

    Let's first go back to EXAM. We need 55 more events after June, 2012. If the exponential curve held, we would reach that point before Dec 2013. It seems EXAM will last for a few months. If cometriq really did extreme miracle for the rest of patients, we may have to wait 10 more years. That a good thing, we already got approval anyway.
    COMET-1's interim trigger is 387 events. We reached full enrollment on Sept 2013. Enrollment started long before that time. If we didn't get 387 on March, there is no chance we will get 578 on June2014. And we will cross our collective fingers wishing not getting that result on June. It will be a funny and worrisome waiting, waiting for something to come that we wish not to come so soon.

  • Reply to


    by philalethes18 Mar 20, 2014 5:45 PM
    stocklooking stocklooking Mar 20, 2014 6:47 PM Flag

    Sold shares to GS way too cheap, not good at dealing with FDA.
    And most important, focus too much on his hair.

  • Reply to

    I exited-Here is Why- Part 1 of 2

    by symptoms88 Mar 18, 2014 2:14 PM
    stocklooking stocklooking Mar 20, 2014 1:57 PM Flag

    traders and investors on one great idea don't share the same mindset. no need to argue.

22.09-0.20(-0.90%)Apr 16 4:01 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.